|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI
|
|
2
|
Engstrand J, Nilsson H, Strömberg C, Jonas
E and Freedman J: Colorectal cancer liver metastases-a
population-based study on incidence, management and survival. BMC
Cancer. 18:782018.PubMed/NCBI
|
|
3
|
Brodt P: Role of the microenvironment in
liver metastasis: From Pre- to prometastatic niches. Clin Cancer
Res. 22:5971–5982. 2016.PubMed/NCBI
|
|
4
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol.
27:1386–1422. 2016.PubMed/NCBI
|
|
5
|
Zarour LR, Anand S, Billingsley KG, Bisson
WH, Cercek A, Clarke MF, Coussens LM, Gast CE, Geltzeiler CB,
Hansen L, et al: Colorectal cancer liver metastasis: Evolving
paradigms and future directions. Cell Mol Gastroenterol Hepatol.
3:163–173. 2017.PubMed/NCBI
|
|
6
|
Wang Y, Ding Y, Guo N and Wang S: MDSCs:
Key Criminals of Tumor Pre-metastatic Niche Formation. Front
Immunol. 10:1722019.PubMed/NCBI
|
|
7
|
Wang D, Sun H, Wei J, Cen B and DuBois RN:
CXCL1 is critical for premetastatic niche formation and metastasis
in colorectal cancer. Cancer Res. 77:3655–3665. 2017.PubMed/NCBI
|
|
8
|
Eveno C, Hainaud P, Rampanou A, Bonnin P,
Bakhouche S, Dupuy E, Contreres JO and Pocard M: Proof of
prometastatic niche induction by hepatic stellate cells. J Surg
Res. 194:496–504. 2015.PubMed/NCBI
|
|
9
|
Cesselli D, Beltrami AP, Poz A, Marzinotto
S, Comisso E, Bergamin N, Bourkoula E, Pucer A, Puppato E,
Toffoletto B, et al: Role of tumor associated fibroblasts in human
liver regeneration, cirrhosis, and cancer. Int J Hepatol.
2011:1209252011.PubMed/NCBI
|
|
10
|
Cassiman D, Libbrecht L, Desmet V, Denef C
and Roskams T: Hepatic stellate cell/myofibroblast subpopulations
in fibrotic human and rat livers. J Hepatol. 36:200–209.
2002.PubMed/NCBI
|
|
11
|
Terada T, Makimoto K, Terayama N, Suzuki Y
and Nakanuma Y: Alpha-smooth muscle actin-positive stromal cells in
cholangiocarcinomas, hepatocellular carcinomas and metastatic liver
carcinomas. J Hepatol. 24:706–712. 1996.PubMed/NCBI
|
|
12
|
Lei X, Deng L, Liu D, Liao S, Dai H, Li J,
Rong J, Wang Z, Huang G, Tang C, et al: ARHGEF7 promotes metastasis
of colorectal adenocarcinoma by regulating the motility of cancer
cells. Int J Oncol. 53:1980–1996. 2018.PubMed/NCBI
|
|
13
|
Ju M, Qiu S, Fan J, Xiao Y, Gao Q, Zhou J,
Li Y and Tang Z: Peritumoral activated hepatic stellate cells
predict poor clinical outcome in hepatocellular carcinoma after
curative resection. Am J Clin Pathol. 131:498–510. 2009.PubMed/NCBI
|
|
14
|
Guirouilh J, Castroviejo M, Balabaud C,
Desmouliere A and Rosenbaum J: Hepatocarcinoma cells stimulate
hepatocyte growth factor secretion in human liver myofibroblasts.
Int J Oncol. 17:777–781. 2000.PubMed/NCBI
|
|
15
|
Guinney J, Dienstmann R, Wang X, de
Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda
G, Angelino P, et al: The consensus molecular subtypes of
colorectal cancer. Nat Med. 21:1350–1356. 2015.PubMed/NCBI
|
|
16
|
Sahani DV, Bajwa MA, Andrabi Y, Bajpai S
and Cusack JC: Current status of imaging and emerging techniques to
evaluate liver metastases from colorectal carcinoma. Ann Surg.
259:861–872. 2014.PubMed/NCBI
|
|
17
|
Klein CA: Cancer. The metastasis cascade.
Science. 321:1785–1787. 2008.PubMed/NCBI
|
|
18
|
Liu Y and Cao X: Characteristics and
significance of the Pre-metastatic niche. Cancer Cell. 30:668–681.
2016.PubMed/NCBI
|
|
19
|
Kaplan RN, Riba RD, Zacharoulis S, Bramley
AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, et
al: VEGFR1-positive haematopoietic bone marrow progenitors initiate
the pre-metastatic niche. Nature. 438:820–827. 2005.PubMed/NCBI
|
|
20
|
Kang N, Gores GJ and Shah VH: Hepatic
stellate cells: Partners in crime for liver metastases? Hepatology.
54:707–713. 2011.PubMed/NCBI
|
|
21
|
Tejpar S, Stintzing S, Ciardiello F,
Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ and Heinemann
V: Prognostic and predictive relevance of primary tumor location in
patients with RAS Wild-type metastatic colorectal cancer:
Retrospective analyses of the CRYSTAL and FIRE-3 Trials. JAMA
Oncol. 3:194–201. 2017.PubMed/NCBI
|
|
22
|
Ayez N, van der Stok EP, Grünhagen DJ,
Rothbarth J, van Meerten E, Eggermont AM and Verhoef C: The use of
neo-adjuvant chemotherapy in patients with resectable colorectal
liver metastases: Clinical risk score as possible discriminator.
Eur J Surg Oncol. 41:859–867. 2015.PubMed/NCBI
|
|
23
|
Fong Y, Fortner J, Sun RL, Brennan MF and
Blumgart LH: Clinical score for predicting recurrence after hepatic
resection for metastatic colorectal cancer: Analysis of 1001
consecutive cases. Ann Surg. 230:309–321. 1999.PubMed/NCBI
|
|
24
|
Sceneay J, Smyth MJ and Moller A: The
pre-metastatic niche: Finding common ground. Cancer Metastasis Rev.
32:449–464. 2013.PubMed/NCBI
|
|
25
|
Mikuriya Y, Tashiro H, Kuroda S, Nambu J,
Kobayashi T, Amano H, Tanaka Y and Ohdan H: Fatty liver creates a
pro-metastatic microenvironment for hepatocellular carcinoma
through activation of hepatic stellate cells. Int J Cancer.
136:E3–E13. 2015.PubMed/NCBI
|
|
26
|
Zuo K, Qi Y, Yuan C, Jiang L, Xu P, Hu J,
Huang M and Li J: Specifically targeting cancer proliferation and
metastasis processes: the development of matriptase inhibitors.
Cancer Metastasis Rev. 38:507–524. 2019.PubMed/NCBI
|
|
27
|
Ma TH, Gao CC, Xie R, Yang XZ, Dai WJ,
Zhang JL, Yan W and Wu SN: Predictive values of FAP and HGF for
tumor angiogenesis and metastasis in colorectal cancer. Neoplasma.
64:880–886. 2017.PubMed/NCBI
|
